>
NeuroScientific Biopharmaceuticals logo

NSB - NeuroScientific Biopharmaceuticals Share Price

A$0.4 0.0  0.0%

Last Trade - 5:59am

Sector
Healthcare
Size
Micro Cap
Market Cap £31.0m
Enterprise Value £23.3m
Revenue £565k
Position in Universe 1141st / 1954
Bullish
Bearish
Unlock NSB Revenue
Momentum
Relative Strength (%)
1m -12.9%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -25.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2016 2017 2018 2019 2020 2021 2022E 2023E CAGR / Avg
0.000 0.038 0.029 0.12 0.076 1.05 +710%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 30 June 2021,Neuroscientific Biopharmaceuticals Ltd revenues increasedfrom A$76K to A$1M. Net loss increased 11% to A$3.2M.Revenues reflect Other Income increase from A$41K to A$1M.Higher net loss reflects Research and development expensesincrease of 56% to A$2.2M (expense), AdministrationExpenses increase from A$163K to A$393K (expense), Sharebased payment increase of 26% to A$626K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

NSB Revenue Unlock NSB Revenue

Net Income

NSB Net Income Unlock NSB Revenue

Normalised EPS

NSB Normalised EPS Unlock NSB Revenue

PE Ratio Range

NSB PE Ratio Range Unlock NSB Revenue

Dividend Yield Range

NSB Dividend Yield Range Unlock NSB Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
NSB EPS Forecasts Unlock NSB Revenue
Profile Summary

NeuroScientific Biopharmaceuticals Ltd is an Australia-based company, which develops peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with unmet medical demand. The company’s product portfolio includes EmtinB, a therapeutic peptide initially targeting Alzheimer’s disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn), which have demonstrated similar therapeutic potential as EmtinB. EmtinB is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinBTM is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body’s innate immune response to cell injury.

Directors
Last Annual June 30th, 2021
Last Interim June 30th, 2021
Incorporated November 14, 2002
Public Since July 27, 2018
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 143,471,643
Free Float (0.0%)
Eligible for
ISAs
SIPPs
NSB Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for NSB
Upcoming Events for NSB
Monday 25th October, 2021
NeuroScientific Biopharmaceuticals Ltd at EBD Group BIO-Europe (Virtual)
Thursday 11th November, 2021
NeuroScientific Biopharmaceuticals Ltd Annual Shareholders Meeting
Tuesday 7th December, 2021 Estimate
NeuroScientific Biopharmaceuticals Ltd Annual Shareholders Meeting
Frequently Asked Questions for NeuroScientific Biopharmaceuticals
What is the NeuroScientific Biopharmaceuticals share price?

As of 5:59am, shares in NeuroScientific Biopharmaceuticals are trading at A$0.4, giving the company a market capitalisation of £31.0m. This share price information is delayed by 15 minutes.

How has the NeuroScientific Biopharmaceuticals share price performed this year?

Shares in NeuroScientific Biopharmaceuticals are currently trading at A$0.4 and the price has moved by 23.08% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the NeuroScientific Biopharmaceuticals price has moved by 3% over the past year.

What are the analyst and broker recommendations for NeuroScientific Biopharmaceuticals?

There are no analysts currently covering NeuroScientific Biopharmaceuticals.

When will NeuroScientific Biopharmaceuticals next release its financial results?

NeuroScientific Biopharmaceuticals is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-06-30
What is the NeuroScientific Biopharmaceuticals dividend yield?

NeuroScientific Biopharmaceuticals does not currently pay a dividend.

Does NeuroScientific Biopharmaceuticals pay a dividend?

NeuroScientific Biopharmaceuticals does not currently pay a dividend.

When does NeuroScientific Biopharmaceuticals next pay dividends?

NeuroScientific Biopharmaceuticals does not currently pay a dividend.

How do I buy NeuroScientific Biopharmaceuticals shares?

To buy shares in NeuroScientific Biopharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of NeuroScientific Biopharmaceuticals?

Shares in NeuroScientific Biopharmaceuticals are currently trading at A$0.4, giving the company a market capitalisation of £31.0m.

Where are NeuroScientific Biopharmaceuticals shares listed? Where are NeuroScientific Biopharmaceuticals shares listed?

Here are the trading details for NeuroScientific Biopharmaceuticals:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: NSB
What kind of share is NeuroScientific Biopharmaceuticals?

Based on an overall assessment of its quality, value and momentum, NeuroScientific Biopharmaceuticals is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a NeuroScientific Biopharmaceuticals share price forecast 2021?

We were not able to load any forecast data for NeuroScientific Biopharmaceuticals.

How can I tell whether the NeuroScientific Biopharmaceuticals share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like NeuroScientific Biopharmaceuticals. Over the past six months, the relative strength of its shares against the market has been 33.45%. At the current price of A$0.4, shares in NeuroScientific Biopharmaceuticals are trading at 33.5% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the NeuroScientific Biopharmaceuticals PE Ratio?

We were not able to find PE ratio data for NeuroScientific Biopharmaceuticals.

Who are the key directors of NeuroScientific Biopharmaceuticals?

NeuroScientific Biopharmaceuticals's management team is headed by:

Matthew Liddelow - CEO
Anton Uvarov - EDR
Paul Rennie - NEC
Stephen Quantrill - NED
Abby Macnish Niven - CFO
Who are the major shareholders of NeuroScientific Biopharmaceuticals?

Here are the top five shareholders of NeuroScientific Biopharmaceuticals based on the size of their shareholding:

McRae Technology Pty. Ltd. Corporation
Percentage owned: 13.33% (19.1m shares)
McRae Investments Pty. Ltd. Venture Capital
Percentage owned: 4.27% (6.13m shares)
Gettingby (Edward Joseph) Individual Investor
Percentage owned: 2.5% (3.59m shares)
Utas Holdings Pty. Ltd. Corporation
Percentage owned: 1.97% (2.82m shares)
ECU Holdings Pty. Ltd. Corporation
Percentage owned: 1.78% (2.56m shares)
Similar to NSB
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.